Purchase Order #75N98026P01685

Pharmacogenomic Analysis Services Contract Awarded to Novogene Corporation

This is a purchase order contract awarded to Novogene Corporation Inc, a company specializing in genomic and pharmacogenomic services, to conduct pharmacogenomic analysis for participants in the STAR-B randomized clinical trial investigating semaglutide as a treatment for alcohol use disorder. The contract supports a critical phase of the clinical trial by providing genetic analysis services that help understand patient responses to the drug, contributing valuable insights to the medical research community and advancing addiction treatment options. The scope of work includes the comprehensive genetic analysis of trial participants' data to identify biomarkers and genetic factors influencing treatment outcomes. This contract was awarded through a competitive acquisition process based on specialized expertise required for this niche scientific service. The period of performance covers a year-long engagement from the fall of 2026 to the fall of 2027, ensuring timely delivery of results aligned with the trial's milestones. Performance will take place in Sacramento, California, supporting logistical coordination with clinical research teams locally.

Description

PHARMACOGENOMIC ANALYSIS SERVICES OF PARTICIPANTS ENROLLED IN THE STAR-B RANDOMIZED CLINICAL TRIAL OF SEMAGLUTIDE FOR ALCOHOL USE DISORDER

View original record